A groundbreaking clinical trial has unveiled promising results for women battling a particularly aggressive form of ovarian cancer, suggesting that a repurposed medication may significantly enhance survival rates. The drug, known as relacorilant, originally designed to treat Cushing’s syndrome, has demonstrated its potential to improve outcomes for patients whose cancer has resisted conventional platinum-based chemotherapy.
The Challenge of Platinum-Resistant Ovarian Cancer
Ovarian cancer ranks as the sixth most prevalent cancer among women in the UK, with approximately 7,600 new diagnoses each year. Unfortunately, for those facing platinum-resistant ovarian cancer—a variant that emerges when the disease progresses within six months of starting platinum chemotherapy—treatment options have been dishearteningly limited. Patients diagnosed with this aggressive form typically have an average life expectancy of only one year post-diagnosis.
Platinum-based chemotherapy employs compounds containing platinum to target and eradicate cancer cells by disrupting their ability to divide. Yet, for many, this approach ceases to be effective, leaving them with few avenues for treatment.
Promising Results from Clinical Trials
A recent study published in *The Lancet* scrutinised the outcomes of 381 patients grappling with platinum-resistant ovarian cancer. Participants received either the standard treatment or relacorilant, a pill intended for those suffering from elevated cortisol levels due to Cushing’s syndrome. After two years of follow-up, the results were striking: patients treated with relacorilant experienced a 35% reduction in the risk of death compared to those receiving standard care. On average, those in the relacorilant group lived four months longer than those in the control group.
These findings have generated considerable excitement within the medical community, suggesting that relacorilant may pave the way for a new standard treatment for patients with this challenging diagnosis.
The Role of Pembrolizumab in Treatment
In conjunction with the promising results for relacorilant, another study involving 643 patients has highlighted the efficacy of pembrolizumab, an immunotherapy drug. This treatment, when administered alongside usual care, allowed patients to live an average of 17.7 months—three months longer than those who received only standard treatment. Pembrolizumab functions by enhancing the immune system’s ability to target and destroy cancer cells, providing a vital alternative for patients whose cancer has become resistant to other therapies.
Regulatory Hurdles Ahead
Both clinical trials for relacorilant and pembrolizumab are currently in phase 3, which means they will require additional testing before receiving approval in the UK. However, it is worth noting that both drugs have already gained approval in the United States from the Food and Drug Administration for use in treating platinum-resistant ovarian cancer, signalling a potential shift in treatment paradigms across the Atlantic.
Why it Matters
The implications of these findings are profound, not only for the patients and families affected by ovarian cancer but also for the broader landscape of cancer treatment. With approximately 3,900 deaths from ovarian cancer each year in the UK, the prospect of effective new therapies offers hope where previously there was little. As researchers continue to explore these promising avenues, the hope is that lives can be saved and the burden of this devastating disease alleviated, ultimately transforming the narrative for countless women facing this formidable diagnosis.
